Summary
PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client. This management contract was one of the largest on record in the ongoing research for multiple myeloma treatment. PRA’s clinical team provided enhanced communication and site support, enabling PRA to streamline regulatory document collection to quickly activate sites. Approved by the FDA after a 4-month accelerated approval process, the drug is the first in a new class of anti-cancer agents called proteasome inhibitors.
Register to download
PRA Leads Novel Multiple Myeloma Drug Development
You may also be interested in:
Case Study
PRA Revs Up Multiple Myeloma Study
A large biotech company selected PRA to conduct 2 global Phase III open-label studies to measure the safety and efficacy of a multiple myeloma drug.…
page
Medical Director
At PRA, Medical Directors have the unique opportunity to impact a broad patient population while staying focused on their therapeutic area of…
page
Privacy Notice
At PRA, we are committed to protecting your privacy. This notice explains how we collect, use, and protect personal information that we obtain…